重组人粒细胞集落刺激因子不良反应的文献分析  

Literature analysis of adverse reactions of recombinant human granulocyte colony-stimulating factor

作　　者：李舜[1] 郭益静[1] 陈力[2] 

机构地区：[1]都江堰市人民医院,成都611830 [2]四川大学华西第二医院,成都610041

出　　处：《中南药学》2011年第12期932-936,共5页Central South Pharmacy

摘　　要：目的通过文献分析方法,汇总重组人粒细胞集落刺激因子使用后不同系统的不良反应发生情况及其与剂量、剂型的关系,为临床更安全的用药提供参考。方法本研究检索了PubMed、EMBASE、Cochrane library、中国生物医学数据库(CBM)、CNKI、VIP等文献数据库,纳入了所有重组人粒细胞集落刺激因子的临床实验和临床研究,对相应安全性指标进行数据提取,进行综合分析。结果从目前的文献报道来看,用于化疗后骨髓抑制时,rhG-CSF不良反应发生率低,患者耐受性较好,主要的不良反应集中在高剂量治疗时的骨骼肌肉痛、头痛、乏力等方面。结论化疗后预防骨髓抑制日剂量应<5μg.kg-1,骨髓动员日剂量<8.8μg.kg-1,可以明显减少rhG-CSF的不良反应发生。Objective To sum up all the reports published on recombinant human granulocyte colony stimulating fac tor （rhG-CSF） adverse reactions in different systems by literature research, to provide clinical reference by deter- mining the relation between the dosage and formulation with the adverse reactions of rhG-CSF. Methods We searched PubMed, EMBASE, Cochrane library, CBM, CNKI, VIP and other literature databases which included all rhG-CSFs in clinical trials and clinical studies, and analyzed all the safety data. Results Adverse reactions caused by rhG-CSF used after chemotherapy rarely occurred and could be tolerated by patients. The main adverse reactions that caused by high doses of treatment showed skeletal muscle pain, headache, fatigue and so on. Conclu- sion rhG-CSF can significantly reduce the incidence of adverse reactions on the prevention of bone marrow suppres- sion after chemotherapy. The daily dose should be less than 5μg · kg^-1, while the bone marrow mobilization dai- ly dose should be less than 8.8μg · kg^-1.

关 键 词：重组人粒细胞集落刺激因子 不良反应 文献分析 

分 类 号：R969.3[医药卫生—药理学] R979.1[医药卫生—药学]